
    
      This is a Phase 1, open-label, multi-center, single treatment study in subjects with normal
      renal function and varying degrees of renal impairment. Each subject will receive a single
      oral dose of lorlatinib administered in the fasted state. Subjects with mild, moderate, and
      severe renal impairment will be enrolled and normal healthy subjects will be enrolled as
      matched controls.
    
  